Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSG-0002 in Chronic Hepatitis B
NCT05760781Phase 2Terminated
- Sponsor
- Staidson Biopharmaceutical
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of STSG-0002 in Chronic Hepatitis B (CHB), sponsored by Staidson Biopharmaceutical. Started Apr 2023; status: terminated.
02
Drugs
STSG-0002
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05760781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760781.